PDF(Pubmed)
Abstract：
Objectives: This systematic review was designed to summarize randomized controlled trials of intra-articular administration of non-steroidal anti-inflammatory drugs (NSAIDs) for temporomandibular disorders. Methods: Randomized controlled trials regarding intra-articular injections of non-steroidal anti-inflammatory drugs for temporomandibular disorders were included in the review. The final search was conducted on 16 June 2024 in the Bielefeld Academic Search Engine, PubMed, and Scopus databases. Results: Of the 173 identified studies, 6 were eligible for review. In trials comparing arthrocentesis alone to arthrocentesis with NSAIDs, slight differences in joint pain were noted. For tenoxicam, differences were under 1 point on a 0-10 scale after 4 weeks, with inconsistent results. Piroxicam showed no significant difference, and pain levels were minimal in both groups. For maximum mouth opening (MMO), tenoxicam showed no significant difference. Piroxicam increased MMO by nearly 5 mm, based on one small trial with bias concerns. Conclusions: Currently, there is no strong scientific evidence supporting the injection of NSAIDs into the temporomandibular joint to relieve pain or increase jaw movement. Preliminary reports on piroxicam with arthrocentesis and tenoxicam or diclofenac without rinsing justify further research.
摘要：
目的：本系统综述旨在总结非甾体抗炎药（NSAIDs）关节内给药治疗颞下颌关节紊乱病的随机对照试验。方法：该综述包括关于关节内注射非甾体抗炎药治疗颞下颌关节紊乱病的随机对照试验。最终搜索于2024年6月16日在比勒费尔德学术搜索引擎中进行，PubMed,和Scopus数据库。结果：在173项确定的研究中，6人符合审查条件。在比较单独关节穿刺术与使用NSAIDs的关节穿刺术的试验中，关节疼痛有轻微差异。对于替诺昔康，4周后在0-10量表上的差异低于1点，结果不一致。吡罗昔康无显著差异,两组的疼痛程度都很低。对于最大开口(MMO),替诺昔康无显著差异。吡罗昔康将MMO增加了近5毫米，基于一项带有偏见的小型试验。结论：目前，没有强有力的科学证据支持向颞下颌关节注射NSAIDs以缓解疼痛或增加下颌运动。关于吡罗昔康与关节穿刺术和替诺昔康或双氯芬酸未经冲洗的初步报告证明了进一步的研究。
